FRAMINGHAM, Mass., Oct. 28, 2015 /PRNewswire/ -- HeartWare
International, Inc. (NASDAQ: HTWR), a leading innovator of
less-invasive, miniaturized circulatory support technologies that
are revolutionizing the treatment of advanced heart failure, today
announced that it will be hosting an analyst and investor meeting
on November 5, 2015 from 9:00 a.m. ET until 1:00 p.m. ET. The
meeting will be webcast live at http://ir.heartware.com, and a
replay will be made available following conclusion of the
meeting.
HeartWare senior management will discuss the company's business
outlook and provide commentary on HeartWare's announced acquisition
of Valtech Cardio, Ltd., a privately held company that specializes
in the development of innovative surgical and transcatheter valve
repair and replacement devices for the treatment of mitral and
tricuspid valve regurgitation. HeartWare's senior management will
be joined by Valtech's senior management, as well as a renowned
panel of international clinicians with experience in ventricular
assist devices and mitral and tricuspid valve regurgitation
interventions, including:
- Prof. Karl-Heinz Kuck, M.D.,
Ph.D. – Asklepios Klinik St. Georg, Hamburg, Germany
- Michael Mack, M.D., FACC –
Baylor Health Care System, Plano,
Texas, USA
- Prof. Francesco Maisano, M.D. –
University Hospital of Zurich,
Zurich, Switzerland
- Paul Grayburn, M.D., FACC –
Baylor University Medical Center,
Dallas, Texas, USA
- Paul Jansz, M.D. – St. Vincent's
Hospital, Sydney, Australia
- Steven Boyce, M.D. – MedStar
Washington Hospital, Washington,
D.C., USA
As part of the meeting, HeartWare and Valtech will each conduct
product demonstrations before and after the presentations.
The live webcast will be accessible on HeartWare's website at
http://ir.heartware.com. A replay of the webcast will be
available through the same link above following completion of the
presentation. A slide presentation to accompany commentary
will be made available just prior to the start of the event in the
Investors section of HeartWare's website at
http://ir.heartware.com.
About Valtech Cardio, Ltd.
Valtech Cardio, Ltd., founded in 2005, is a privately held
company specializing in the development of devices for mitral and
tricuspid valve repair and replacement. Valtech has full
in-house development, manufacturing, and clinical research
capabilities, and over 150 patents and patent applications.
The company, comprised of multidisciplinary development teams,
works in close collaboration with world-renowned heart specialists
to provide the best possible therapy for mitral patients.
Funded in part from investments made by HeartWare International,
Inc. (Nasdaq: HTWR) and other private investors, Valtech is
headquartered in Or Yehuda, Israel. For more information,
visit the company's website: www.valtechcardio.com.
About HeartWare International
HeartWare International, Inc. develops and manufactures
miniaturized implantable heart pumps, or ventricular assist
devices, to treat patients suffering from advanced heart failure.
The HeartWare® Ventricular Assist System features the
HVAD® pump, a small, full-support circulatory assist
device designed to be implanted next to the heart, avoiding the
abdominal surgery generally required to implant competing devices.
The HeartWare HVAD System is approved in the United States for the intended use as a
bridge to cardiac transplantation in patients who are at risk of
death from refractory end-stage left ventricular heart failure, has
received CE Marking in the European Union and has been used to
treat patients in 46 countries. The device is also currently the
subject of a U.S. clinical trial for destination therapy. For
additional information, please visit
www.heartware.com.
Participants in the Solicitation
HeartWare, Valtech and their respective directors, executive
officers, certain members of management and certain employees may
be deemed to be participants in the solicitation of proxies in
connection with the proposed transaction. A description of the
interests in HeartWare of its directors and executive officers is
set forth in HeartWare's proxy statement for its 2015 Annual
Meeting of Shareholders, which was filed with the Securities and
Exchange Commission (the "SEC") on April 30,
2015. This document is available free of charge at the SEC's
website at www.sec.gov or by going to HeartWare's Investors page on
its corporate website at www.heartware.com. Additional
information regarding the persons who may, under the rules of the
SEC, be deemed participants in the solicitation of proxies in
connection with the proposed transaction, and a description of
their direct and indirect interests in the proposed transaction,
which may differ from the interests of HeartWare stockholders or
Valtech shareholders generally, was set forth in a preliminary
proxy statement/prospectus on file with the SEC.
Additional Information about the Transactions and Where to
Find It
In connection with the proposed Transactions, Holdco has filed a
Registration Statement on Form S-4 that contains a preliminary
proxy statement/prospectus, which is not yet final and will be
amended. Holdco intends to file a final prospectus and other
relevant materials and HeartWare intends to file a definitive proxy
statement and other relevant materials with the SEC in connection
with the proposed Transactions. Investors and security holders of
HeartWare and Valtech are urged to read these materials when they
become available because they will contain important information
about HeartWare, Valtech and the Transactions. The proxy
statement/prospectus and other relevant materials (when they become
available), and any other documents filed by Holdco or HeartWare
with the SEC, may be obtained free of charge at the SEC web site at
www.sec.gov. In addition, investors and security holders may obtain
free copies of the documents filed with the SEC by Holdco or
HeartWare by directing a written request to HeartWare's investor
relations department at HeartWare International, Inc., 500 Old
Connecticut Path, Framingham, MA
01701, Attention: Investor Relations. Investors and security
holders are urged to read the proxy statement/prospectus and the
other relevant materials when they become available before making
any voting or investment decision with respect to the
Transactions.
This communication shall not constitute an offer to sell or the
solicitation of an offer to sell or the solicitation of an offer to
buy any securities, nor shall there be any sale of securities in
any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No offering of securities
shall be made except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act of 1933, as
amended (the "Securities Act").
Forward-Looking Statements
This announcement contains forward-looking statements that are
based on management's beliefs, assumptions and expectations and on
information currently available to management. All statements that
address operating performance, events or developments that we
expect or anticipate will occur in the future are forward-looking
statements, including without limitation our expectations with
respect to the: commercialization of HeartWare and Valtech
products; timing, progress and outcomes of clinical trials and
regulatory approvals; research and development activities; our
ability to integrate, manage and take advantage of acquired and
pipeline technology; and the costs and benefits to be achieved from
the Valtech transaction. Management believes that these
forward-looking statements are reasonable as and when made.
However, you should not place undue reliance on forward-looking
statements because they speak only as of the date when made.
HeartWare does not assume any obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as may be required
by federal securities laws and the rules and regulations of the
SEC. HeartWare may not actually achieve the plans, projections or
expectations disclosed in forward-looking statements, and actual
results, developments or events could differ materially from those
disclosed in the forward-looking statements. Forward-looking
statements are subject to a number of risks and uncertainties,
including without limitation those described in Part I, Item 1A
"Risk Factors" in HeartWare's Annual Report on Form 10-K filed with
the SEC. HeartWare may update risk factors from time to time in
Part II, Item 1A "Risk Factors" in Quarterly Reports on Form 10-Q,
Current Reports on Form 8-K, or other filings with the SEC.
HEARTWARE, HVAD, MVAD, PAL, SYNERGY, CIRCULITE and HeartWare
logos are trademarks of HeartWare, Inc. or its affiliates.
VALTECH, CARDIOBAND, CARDINAL, CARDIOVALVE, V-CHORDAL and
Valtech logos are trademarks of Valtech Cardio, Ltd.
For additional information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartware.com
Phone: +1 508 739 0864
Logo - http://photos.prnewswire.com/prnh/20150901/262901LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/heartware-international-analyst-and-investor-meeting-on-november-5-2015-to-be-webcast-300167817.html
SOURCE HeartWare International, Inc.